Latest News
Fixing the Wrong Problem: How Healthcare Misdiagnoses its Workforce Crisis
The healthcare sector has a burnout problem it keeps trying to solve with the wrong tools. Across Australia and globally, rates of psychological distress, absenteeism and early career exit among healthcare workers have reached levels that can no longer be attributed...
Latest News
Clinical Trials Roundup | 22 May 2026
Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...
LillyPod Drug Discovery: Lilly’s NVIDIA Supercomputer Explained
Eli Lilly has switched on what it describes as the most powerful supercomputer ever owned and operated by a pharmaceutical company, and the implications for LillyPod drug discovery could reshape how medicines are found, tested, and delivered. Inaugurated in February...
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift
The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...
Why Human-Led Billing is Making a Comeback in AI-Driven Healthcare System
For the past several years, the prevailing narrative in healthcare revenue cycle management has been straightforward: automate everything, reduce human touchpoints, and let artificial intelligence handle the complexity. The promise was compelling: faster claims...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Radiopharmaceuticals: The Cancer Treatment Reshaping Oncology
For decades, oncology ran on a handful of dominant modalities: surgery, chemotherapy, and radiotherapy, later joined by targeted therapies and immunotherapy. Radiopharmaceuticals have now entered that conversation as a serious contender. These drugs combine a...
Why Neurology Clinical Trials Need Purpose-Built AI
Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...
What the Veppanu Approval Means for ESR1 Breast Cancer
The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...
Burnout in the Helping Profession: Why Healthcare Keeps Getting it Wrong
Across the life sciences sector, a quiet crisis is unfolding. Researchers, clinicians, nurses, and social workers describe feeling trapped in a cycle with no exit: outwardly productive, inwardly depleted. Burnout is not a new phenomenon, but the life sciences...
Agentic AI in Drug Discovery: Why Big Pharma is All in
When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....
Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis
Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Weekly News Roundup | 18 May 2026
Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...
Biologics on the Brink: The Patent Cliff Facing Big Pharma
The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
Clinical Trials Roundup | 15 May 2026
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
GLP-1 Receptor Agonists Explained: How They Work and Who They’re For
What Are GLP-1 Receptor Agonists? GLP-1 receptor agonists have become one of the most talked-about drug classes in modern medicine. Originally developed to treat type 2 diabetes, these medicines now carry approved indications spanning obesity, cardiovascular disease,...
Radiopharmaceuticals: The Cancer Treatment Reshaping Oncology
For decades, oncology ran on a handful of dominant modalities: surgery, chemotherapy, and radiotherapy, later joined by targeted therapies and immunotherapy. Radiopharmaceuticals have now entered that conversation as a serious contender. These drugs combine a...
Why Neurology Clinical Trials Need Purpose-Built AI
Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...
What the Veppanu Approval Means for ESR1 Breast Cancer
The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...
Burnout in the Helping Profession: Why Healthcare Keeps Getting it Wrong
Across the life sciences sector, a quiet crisis is unfolding. Researchers, clinicians, nurses, and social workers describe feeling trapped in a cycle with no exit: outwardly productive, inwardly depleted. Burnout is not a new phenomenon, but the life sciences...
Agentic AI in Drug Discovery: Why Big Pharma is All in
When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....
Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis
Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Weekly News Roundup | 18 May 2026
Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...
Biologics on the Brink: The Patent Cliff Facing Big Pharma
The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
Clinical Trials Roundup | 15 May 2026
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
GLP-1 Receptor Agonists Explained: How They Work and Who They’re For
What Are GLP-1 Receptor Agonists? GLP-1 receptor agonists have become one of the most talked-about drug classes in modern medicine. Originally developed to treat type 2 diabetes, these medicines now carry approved indications spanning obesity, cardiovascular disease,...
Featured Articles
Further News
Hallmarks of Ageing as a Framework: How the Research Field is Evolving
When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
Biotech M&A 2026: Every $1B+ Deal so Far and What is Driving Them
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Muscular Dystrophy Has New Treatments. Patients Still Can’t Get Diagnosed
A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...
Beyond GLP-1: The Future of Obesity Care is Hybrid
The emergence of GLP-1 receptor agonists has fundamentally reshaped obesity treatment. For the first time, we are seeing consistent, clinically meaningful weight loss at scale, supported by robust clinical programs such as STEP and SURMOUNT (Wilding et al., 2021;...
Using AI to Translate Fragmented Evidence into Formulation Logic
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Invisible Architect: How Infrastructure Drives Life Sciences Growth
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
Weekly News Roundup | 11 May 2026
Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...
Why “Hot” Therapeutic Areas Break Traditional Benchmarks
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...
Is Photodisinfection the New Alternative to Traditional Antibiotics?
Few ideas in modern medicine are as unsettling as the prospect of a “post-antibiotic era.” For decades, antibiotics have underpinned infection control, transforming once-lethal diseases into manageable conditions. Yet their effectiveness is steadily eroding....
Orforglipron Approved: Inside the Oral GLP-1 Race
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.